Europe Metastatic Cancer Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Indication, By Therapy (Targeted Therapy, Immunotherapy, Hormonal Therapy and Chemotherapy), By Country and Growth Forecast, 2023 - 2030

The Europe Metastatic Cancer Drugs Market should witness market growth of 6.7% CAGR during the forecast period (2023-2030).

Substantial drug discoveryand development improvements have also facilitated the emergence of newer and more potent therapies for metastatic cancer. The treatment landscape has changed dramatically due to the introduction of targeted medicines, immunotherapies, and combination medications, improving patient outcomes. These cutting-edge therapies have increased the demand for metastatic cancer medications and helped the market for these medications expand.

Additionally, regulatory organizations like the European Medicines Agency (EMA) have established programs to speed up the approval process for medications for metastatic cancer. Promising pharmaceuticals can now reach the market more quickly because of fast-track designations, breakthrough therapy designations, and accelerated approvals. The favorable regulatory environment encourages the development of medications to treat metastatic cancer, which propels market expansion.

In the United Kingdom, approximately 48,000 individuals are diagnosed with lung cancer, and 35,000 die annually. According to 2015 data, the United Kingdom's Department of Health and Social Care invests significantly yearly in cancer-related treatment and services. With rise in the number of cancer cases especially the lung cancer patient, the Europe’s market is estimated to grow.

The Germany market dominated the Europe Metastatic Cancer Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,073.5 million by 2030. The UK market is exhibiting a CAGR of 5.8% during (2023-2030). Additionally, The France market would experience a CAGR of 7.5% during (2023-2030).

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Indication, the market is segmented into Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma & Others. Based on Therapy, the market is segmented into Targeted Therapy, Immunotherapy, Hormonal Therapy and Chemotherapy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, Inc. and Sanofi S.A.

Scope of the Study

By Distribution Channel

• Hospital Pharmacies
• Drug Store & Retail Pharmacies
• Online Providers

By Indication

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Melanoma & Others

By Therapy

• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Chemotherapy

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Bristol Myers Squibb Company
• Merck & Co., Inc.
• AstraZeneca PLC
• Novartis AG
• Eli Lilly And Company
• Pfizer, Inc.
• F.Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Amgen, Inc.
• Sanofi S.A.

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free